If you are comparing telehealth clinics for compounded peptide therapy, you are probably someone who reads the research, tracks your sleep and your training, and wants an edge on recovery, body composition or how you will feel at fifty-five. Somewhere along the way a peptide, most often BPC-157, was presented as that edge, sold by subscription, shipped in a vial, with a protocol that fits on a card. You want to know which clinic does it properly.
GoodLife Health does not offer compounded peptide therapy, and we do not prescribe research peptides. This piece explains why, using the FDA's public record with its dates, what "peptide therapy" actually covers, and what we do instead for the person who wants to optimize with evidence rather than with a vial. We have a stake in the answer, so the facts come first and our view is labeled as ours.
- "Peptide therapy" covers two different things: approved peptide medicines, such as semaglutide, tirzepatide and insulin, and research peptides such as BPC-157 that are not approved for any human use.
- BPC-157 is not FDA-approved, and in 2023 the FDA listed it among bulk substances that may present significant safety risks in compounding, citing insufficient human safety data.
- A clinic's lab oversight cannot make an unapproved substance approved; it can only watch what happens after you take it.
- GoodLife Health prescribes FDA-approved medication only, after labs, and never research peptides.
- The evidence-led version of optimization starts with what is measurable: ApoB, Lp(a), fasting insulin, A1C, hs-CRP and thyroid function, every quarter.
Why peptides are being sold to you
The appeal is easy to understand. Peptides are short chains of amino acids, the body makes many of them, and some of the most important medicines of the last decade are peptides. Semaglutide and tirzepatide, the GLP-1 medicines, are peptides. So is insulin. When a seller tells you a peptide can help you heal faster, sleep deeper or lose fat, the claim borrows credibility from medicines that genuinely changed what clinicians can do.
The marketing also fits the way a disciplined person likes to work. A peptide comes with a protocol, a cycle and a dose to track. It feels like a precise intervention, the opposite of the vague advice to sleep more and stress less. And it is easy to buy: a short questionnaire, a prescriber you may never speak to again, and a vial at the door.
None of that is a reason to doubt your instincts about wanting to optimize. It is a reason to separate the medicines that earned their credibility from the substances that are borrowing it.
Two kinds of peptide therapy
The phrase hides a distinction that decides everything.
Approved peptide medicines. These have been through FDA review of safety, effectiveness and manufacturing, they are made to a labeled dose, and their evidence comes from trials of that exact product. GLP-1 medicines such as Wegovy, Ozempic, Zepbound and Mounjaro are in this group. A clinician who prescribes one is prescribing a known product for an indication it was approved for.
Research peptides. BPC-157 is the best known, and it is often sold alongside others marketed for recovery, growth hormone release or longevity. These are not approved for any human use. They reach patients through compounding pharmacies or through vendors that label them for research. Their evidence, where it exists, is mostly from animal and laboratory studies rather than controlled trials in people.
A clinic can be careful, credentialed and well designed and still be selling the second kind. That is why ranking clinics by their oversight misses the point: oversight is about watching what happens after you take something, and it cannot change what the something is.
What the FDA record says about BPC-157
BPC-157 is not FDA-approved for any human condition. In 2023 the FDA listed it among the bulk drug substances that may present significant safety risks when used in compounding, on its page on certain bulk drug substances for use in compounding, citing insufficient information on its safety in humans. That listing restricts licensed compounding pharmacies from using it, which is why much of the supply now moves through vendors that sell it labeled for research rather than through pharmacies at all.
More broadly, the FDA states that compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are sold, a position set out on its page on unapproved GLP-1 drugs and true of compounding generally.
We do not say every peptide vial is dangerous. We say the evidence needed to know whether one is safe and effective in people has not been produced, and that when a clinician prescribes it, that clinician's licence carries the responsibility for a substance no regulator has reviewed. We chose not to put ours there.
If you are taking a research peptide now, tell any clinician who treats you, including the name, the source, the dose and how long you have taken it. Unreported supplements and peptides are among the most common reasons a lab result is misread.


The question the peptide was meant to answer
Most people who start a peptide are trying to fix something real: an injury that heals slowly, recovery that has worsened with age, stubborn fat around the middle, flat energy, poor sleep. Those are worth taking seriously, and each has causes that can be measured.
Slow recovery and stubborn abdominal fat often travel with insulin resistance, which a fasting insulin and an A1C can show years before a glucose result turns abnormal. Low energy can be a thyroid that has drifted, a low iron store, poor sleep, or, in men, low testosterone, each of which shows up in labs. Persistent inflammation shows up in hs-CRP. Cardiovascular risk that no amount of training removes shows up in ApoB and Lp(a), which a standard annual panel rarely includes.
When the cause is found, the treatment is usually an approved one, or no medicine at all: a change in training, protein, sleep or alcohol that the numbers now justify. Where a medicine is indicated, it might be a GLP-1 for insulin resistance and excess weight, thyroid medication, or, where the law allows and a clinician judges it right, testosterone, which is a Schedule III controlled substance prescribed only through our clinical partner's arrangement and never promised by the membership.
Questions to ask any clinic that offers peptides
Whether or not you ever join us, these questions will tell you a great deal about a peptide offer in a few minutes.
Is this product FDA-approved for what you are prescribing it for? If the answer is no, ask what evidence in people supports the claim, and whether it comes from controlled trials or from animal and laboratory work.
Where does it come from? A licensed 503A pharmacy, a registered 503B outsourcing facility, or a vendor selling it for research? Ask for the pharmacy's name and licence, and what the vial's label will say.
What did you measure before deciding I need it? A protocol chosen before any blood is drawn is a product, not a treatment. Ask which labs informed the recommendation and when they will be repeated.
What happens if it does not work, or if something goes wrong? Ask who you contact, how quickly they answer, and what they would check first.
How does the clinic earn its money? If the fee rises with each peptide or each cycle, the incentive is in the stack, not in your result.
A good clinic, of any kind, will welcome these questions. If the answers are vague, that is the answer.
What we do instead
GoodLife Health is a clinician-led membership built for the person who wants to optimize with evidence.
We test first. Every member has four cardiometabolic lab panels a year: ApoB, Lp(a), a lipid panel, fasting insulin, A1C, hs-CRP, TSH with free T4, a comprehensive metabolic panel and a blood count. Every result is in your hands, and you see the trend quarter to quarter.
We treat what the labs show, with approved medicine. When a medication is indicated, our clinicians prescribe FDA-approved medication to the pharmacy you choose, at that pharmacy's own price. We set nothing on it, see nothing on it and take nothing from it.
We do not sell protocols. There are no research peptides, no pellets and no stacks in our formulary, and nothing about the membership fee changes with what is prescribed.
We stay. The same care team by message and video, licensed in all fifty states, reading each panel against the last one.
Where optimization is going
The direction of serious prevention is clear in what it measures. ApoB and Lp(a) are moving into routine cardiovascular assessment where LDL alone used to stand, fasting insulin is being read where glucose used to be the only sugar marker, and the approved peptide medicines, the GLP-1s, have shown how much metabolic health can change when a real medicine meets a measured problem.
What that direction does not include is a substance with no human trials, chosen before anyone has looked at your blood. We think the next decade of optimization belongs to testing before treating, approved medicine where it is indicated, and a clinician who follows the numbers with you. That is the model GoodLife Health runs, and it is why we left research peptides out.
What it costs, what it buys, and what it does not
The GoodLife Health membership is $299 a month, month to month. $598 is held on your card at sign-up, charged only once you are accepted, and covers the first two months. If a clinician cannot accept you into care, the $598 hold is released and you are never charged; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee is the same whatever is prescribed.
It buys the quarterly panel, a clinician who reads it with you and stays, messaging and video visits, and FDA-approved medication prescribed when indicated to your pharmacy at its price. It returns what a peptide subscription never could: the reason you feel the way you do, and the markers to prove what changed. It does not replace your health insurance, and it does not guarantee any result, any particular prescription, or acceptance into care.
Who this is not for
If you want BPC-157 or another research peptide, GoodLife Health is not for you, and we would rather say so now. The membership is also not for someone who wants a prescription without labs, for anyone who wants pellets or compounded medication, for anyone under 18, for someone who needs urgent or full-scope primary care, or for anyone outside the United States. If $299 a month would be a strain, choose care you can sustain.
Oversight can watch what happens after you take something; it cannot change what the something is.
Frequently Asked Questions
Does GoodLife Health offer compounded peptide therapy or BPC-157?
No. Our clinicians prescribe FDA-approved medication only, after labs, and never research peptides such as BPC-157.
Is BPC-157 FDA-approved?
No. BPC-157 is not approved for any human use, and in 2023 the FDA listed it among bulk drug substances that may present significant safety risks in compounding, citing insufficient human safety data.
Are GLP-1 medicines peptides?
Yes. Semaglutide and tirzepatide are peptide medicines, approved by the FDA after review of their safety, effectiveness and manufacturing. That is the difference between an approved peptide medicine and a research peptide.
What does GoodLife Health do instead for recovery, energy and body composition?
We test first: four cardiometabolic panels a year, including ApoB, Lp(a), fasting insulin, A1C, hs-CRP and thyroid function. A clinician treats what the labs show, with approved medication when it is indicated.
Related Reading
- Cardiometabolic Optimization: The Definitive Guide
- Aligned Medicine: How Zero-Markup Healthcare Actually Works
- What Is GoodLife Health?
- Compounded GLP-1 vs Brand Name: What Patients Need to Know
References
- FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2023. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss